Johnson & Johnson will pay $16.6 billion US in cash to buy the consumer health-care unit of drug company Pfizer. The move would add several well-known brand names to J&J's lineup, including Listerine, ...

Pfizer appears to have one-upped Johnson & Johnson again in their PARP inhibitor battle in prostate cancer.  | After winning a broader FDA label in metastatic castration-resistant prostate cancer, ...

Moderna booster shots, Pfizer booster shots and Johnson & Johnson booster shots of the COVID-19 vaccine are now available, following a thorough in-depth review process from the Food and Drug ...

Pfizer Inc. (NYSE: PFE) made a strong move higher after it became the first drug manufacturer to sign on as part of the TrumpRx platform. PFE stock is up nearly 14% since its closing price of around ...

Pfizer’s biggest competitors in the global pharmaceutical industry are Johnson & Johnson, Roche, Eli Lilly, AbbVie, Novo ...

As large tech companies struggled this year, investors have had a chance to reevaluate their portfolios and identify where they may be underexposed to certain sectors. One of those sectors may be ...

Johnson & Johnson’s third-quarter results were strong as it beat estimates for both earnings and sales. JNJ’s Innovative Medicines segment outperformed expectations while MedTech underperformed. Sales ...

AbbVie and Pfizer chart distinct paths in revenue growth, risk, and valuation. Explore how their financials and strategies ...

UPDATE: The U.S. is recommending a “pause” in administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots. In a joint statement ...

Johnson & Johnson is one of the largest pharmaceutical stocks by market cap. Pfizer's dividend offers a hefty yield. Revenue is growing for J&J, while Pfizer is leaning on acquisitions to help spur ...